Firalis Molecular Precision Expands Bioanalytical Capabilities with the Acquisition of the QuantStudio Absolute Q Digital PCR System

Huningue, France – Firalis Molecular Precision (FMP), a CAP-accredited fast-growing Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), announces the addition of the Applied Biosystems QuantStudio Absolute Q Digital PCR System to its PCR portfolio. Powered by Thermo Fisher Scientific’s exclusive Microfluidic Array Plate (MAP) technology, the digital PCR (dPCR) system offers an advanced approach to nucleic acid quantification, further enhancing the company’s services provided to pharmaceutical and biotech organizations and researchers, for clinical trials, drug discovery, and research.

The QuantStudio Absolute Q System is based on digital PCR, a next-generation technique for absolute quantification of nucleic acids without relying on standard curves or amplification efficiency. By partitioning samples into thousands of individual reactions, dPCR enables superior precision and sensitivity, making it an ideal solution for detecting rare mutations, low-abundance targets, and complex biomarker analyses.

This acquisition will complement the company’s existing PCR technology suite, empowering its experts to serve clients across a wide range of bioanalytical applications. While the company will continue to offer traditional qPCR solutions for applications requiring relative quantification and other research needs, dPCR is an ideal choice for researchers seeking high accuracy, absolute quantification, and the ability to detect rare or low-level targets.

The QuantStudio Absolute Q Digital PCR System is designed to support a broad range of bioanalytical applications, including but not limited to:

• Rare mutation detection: Detect low-frequency genetic mutations in oncology, genetic disorders, and liquid biopsy.

• Gene expression profiling: Accurately measure gene expression levels in clinical and research samples, particularly in complex tissues or low-abundance genes.

• Viral load quantification: In clinical trials or infectious disease studies, including HIV, hepatitis, and SARS-CoV-2.

• Copy Number Variation (CNV) analysis: Gives insights into diseases such as cancer and neurological disorders.

• Minimal Residual Disease (MRD) monitoring: Sensitive detection of residual cancer cells, aiding in early relapse detection and treatment monitoring.

• Pathogen detection: Detect and quantify pathogens in clinical samples to support diagnostics and therapeutic decision-making.

“We’re always looking for ways to push the boundaries of what we can offer our clients,” said Dr. Gabriel Sanchez, Head of Genomics at Firalis Molecular Precision. “The QuantStudio Absolute Q is a leap forward in precision and reliability. For applications where sensitivity is important, like rare mutation or low-abundance target detection, it delivers results we can truly stand behind. We’re excited to see the impact it will have on the research and clinical breakthroughs our clients are striving for.“